YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Launched by SHANGHAI YINGLI PHARMACEUTICAL CO. LTD. · Oct 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying new combinations of treatments for patients with metastatic pancreatic cancer, which is a type of cancer that has spread beyond the pancreas. The trial will test two different drug combinations alongside a standard chemotherapy regimen called AG. It aims to find out if these combinations are safe and effective for treating this serious condition. Initially, six participants will be enrolled in two groups to check for safety, and after that, more participants will join a third group that uses all three treatments together.

To be eligible for this trial, participants need to be between 18 and 75 years old and have been diagnosed with metastatic pancreatic ductal adenocarcinoma, which is a specific type of pancreatic cancer. They should have at least one area of cancer that can be measured and should be in relatively good health overall. However, those who may still be candidates for surgery or have different types of cancer are not eligible. Participants can expect to undergo evaluations after their first treatment cycle to ensure their safety before continuing in the study. It's important to know that this trial is not yet recruiting patients, so there will be a wait before it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject aged between 18 and 75 years.
• • Subject has histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.
• • Subject has at least one evaluable metastatic lesion according to RECIST 1.1 criteria;
• • Subject has an ECOG score of 0-1 and is expected to survive more than 3 months;
• • Subjects have a good level of organ function.
• Exclusion Criteria:
• • Subject suitable for potentially curative surgery.
• • The subject confirmed by tissue or cytology as other pathological types, such as acinar cell carcinoma, neuroendocrine carcinoma, etc.
• • The subject has previously received gemcitabine and nab-paclitaxel combination therapy within 6 months of progression or intolerance.